FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP Therapy | HCPLive

Accessed January 5, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-rare-blood-disorder-pediatric-patients-12-years …